In the United States,<unk>  is indicated to treat deep vein thrombosis and pulmonary embolism following five to ten days of initial therapy with a parenteral anticoagulant. It is also indicated to reduce the risk of blood clots in people with nonvalvular atrial fibrillation. In the European Union,<unk>  is indicated for preventing blood clots in people with nonvalvular atrial fibrillation who also have at least one risk factor, such as having had a previous stroke, high blood pressure (hypertension), diabetes mellitus, congestive heart failure or being 75 years of age or older. It is also used to treat deep vein thrombosis and pulmonary embolism and to prevent either of these from reoccurring.
Edoxaban
Clopidogrel
Rivaroxaban
Apixaban
Betrixaban
Dabigatran
Warfarin
Ticagrelor